Markets

Oncolytics Biotech Announces Its Group 4 Of Phase 1/2 GOBLET Trial Of Pelareorep In Combination With Atezolizumab Failed to Reach Median Overall Survival

Oct 27, 2026 · 09:32 AM ET· updated 1h ago

Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced updated data from Cohort 4 of its Phase 1/2 GOBLET

Why It Matters

A medicine test for a cancer treatment did not show the results hoped. When a drug trial misses its main goal, it tells you the company faces a big setback.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ONCY0.46

-0.01 (-2.07%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.